7wireVentures

7wireVentures is one of the cleanest examples of a true digital health specialist, and the firm’s history makes that specialization meaningful. Based in Chicago with approximately $500M in AUM, 7wire was an early backer and incubator of Livongo, the chronic condition management company that defined the modern employer-sponsored digital health category before its $18.5B merger with Teladoc. That single track-record point gives 7wire a credibility in employer health, payer technology, and tech-enabled care delivery that few generalist firms can match. The firm invests across seed through Series B in digital health, care delivery, and health IT, with check sizes from $5M to $25M. For digital health founders, 7wire is a top-tier specialist with deep operating credibility; for non-digital-health founders, the firm is not a fit.

The stated thesis centers on digital health, tech-enabled care delivery, and health IT. The Livongo origin story shapes the firm’s preferences: 7wire favors B2B2C models that distribute through employers, payers, and health systems, with consumer-facing engagement layers that drive measurable clinical and financial outcomes. The implied target company is a team building software-plus-services for chronic condition management, behavioral health, primary care, specialty care, or healthcare administrative workflows, with a credible go-to-market through enterprise buyers. Pure consumer wellness brands without B2B2C anchoring are unlikely to fit. The firm’s positioning explicitly favors capital-efficient companies that can reach commercial inflection without burning excessive capital on direct-to-consumer acquisition.

With specific portfolio names not enumerated in the structured record beyond the Livongo legacy, founders should review the 7wireVentures portfolio page directly. Patterns to watch for include investments in chronic care management beyond diabetes and hypertension, in mental and behavioral health platforms with employer or payer distribution, in care navigation and benefits administration software, and in clinical operations tools serving health systems. The Livongo playbook of remote monitoring plus coaching plus data plus enterprise distribution remains a reference architecture for many of the firm’s bets, and founders pitching variations on that architecture in adjacent disease areas or care models should expect a sympathetic hearing.

Check size at $5M to $25M positions 7wire as a Series A and Series B lead in digital health, with capacity to follow into later rounds for portfolio winners. The firm leads and co-leads at these stages and frequently syndicates with other digital health specialists, employer benefits-focused funds, and select multi-stage firms. Co-investment patterns reflect the firm’s distribution thesis: corporate ventures from large employers, payers, and pharmacy benefit managers appear in syndicate composition for portfolio companies whose go-to-market depends on those channels. Founders should think about syndicate structure in light of customer concentration, and should expect 7wire to push for a syndicate that supports enterprise distribution rather than one optimized only for valuation.

The partnership leadership is concentrated, with senior partners actively involved in investment decisions and board work. While the structured record does not enumerate the full current team, founders should research the firm’s leadership via the website and target the partner with relevant sub-vertical focus. The firm’s connection to Livongo founder Glen Tullman remains a defining feature of the partnership culture, and founders should expect diligence to weight enterprise sales mechanics, clinical evidence generation, and capital efficiency heavily.

Warm intros from Livongo alumni, from senior digital health operators, and from co-investors in prior portfolio companies carry strong signal. The firm is reasonably active publicly within the digital health community, with partner appearances at HLTH, JPMorgan Healthcare Conference, and digital health-focused podcasts including A Healthy Dose and HealthTech Podcast. Founders should pay attention to the firm’s commentary on employer benefits trends, payer adoption of digital health, and the economics of tech-enabled care delivery. Cold inbound is plausible if the deck demonstrates strong B2B2C fundamentals, but warm relationships outperform.

Approach 7wireVentures when you have a digital health company with credible enterprise distribution, measurable outcomes, and capital-efficient unit economics. Do not approach for therapeutics, devices, biotech, or consumer wellness without enterprise anchoring. Among portfolio founders, the firm has a reputation for deeply engaged board partnership, particularly around enterprise sales and clinical strategy, with hands-on support during commercial scaling phases. The Livongo lineage means the firm understands what it takes to build category-defining digital health companies through enterprise channels. For founders aligned on that model, 7wireVentures is one of the more credible specialist options in the market.